USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | - | - | $-0.20 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | - | - | $201.00K |
Baudax Bio, Inc's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 2 | $-0.48 | $-0.51 | $-0.46 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 0 | $-0.48 | $-0.49 | $-0.49 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 2 | $9.35M | $8.40M | $10.30M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 14, 2022 | Dec 2021 | $1.47 | - | - |
| Nov 4, 2021 | Sep 2021 | $-0.16 | $-0.20 | -25.00% |
| Aug 5, 2021 | Jun 2021 | $-0.19 | $-0.20 | -5.26% |
| May 5, 2021 | Mar 2021 | $-0.21 | $-0.27 | -28.57% |
| Feb 16, 2021 | Dec 2020 | $-0.62 | $-0.09 | 85.37% |
| Nov 9, 2020 | Sep 2020 | $-0.58 | $0.62 | 207.83% |
| Aug 10, 2020 | Jun 2020 | $-0.47 | $-1.72 | -269.89% |
| May 8, 2020 | Mar 2020 | $-0.91 | $-4.03 | -342.86% |
| Feb 13, 2020 | Dec 2019 | $-32.78 | $-27.30 | 16.72% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 14, 2022 | Dec 2021 | $-0.80 | $-0.67 | - |
| Feb 16, 2021 | Dec 2020 | $-4.19 | $-5.22 | - |
| Feb 13, 2020 | Dec 2019 | $-3.60 | $-27.30 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 14, 2022 | Dec 2021 | $650.00K | - | - |
| Nov 4, 2021 | Sep 2021 | $600.00K | $281.00K | 0.47% |
| Aug 5, 2021 | Jun 2021 | $201.00K | $201.00K | 1.00% |
| May 5, 2021 | Mar 2021 | $630.00K | $198.00K | 0.31% |
| Feb 16, 2021 | Dec 2020 | $1.63M | $76.00K | 0.05% |
| Nov 9, 2020 | Sep 2020 | $1.00M | $68.00K | 0.07% |
| Aug 10, 2020 | Jun 2020 | $130.00K | $349.00K | 2.68% |
| May 8, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Feb 13, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 14, 2022 | Dec 2021 | $1.35M | - | - |
| Feb 16, 2021 | Dec 2020 | $2.03M | $493.00K | -75.71% |
| Feb 13, 2020 | Dec 2019 | $0.00 | $0.00 | - |
BXRX's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.
Baudax Bio, Inc's previous earnings date was May 3, 2022 for its fiscal quarter ended Mar 31, 2022.
Baudax Bio, Inc's previous annual earnings date was Feb 16, 2021 for its fiscal year ended Dec 31, 2020.
BXRX's earnings per share (EPS) was $-5.22, missing the consensus analysts forecast of $-4.19 by 24.58% , and higher than the previous year's EPS (Dec 2019) by -80.88%.
Revenues were $493.00K.
The company reported a net income of $-76.10M.
Baudax Bio, Inc reported a free cash flow of $-44.70M for its fiscal year, compared to $-51.53M a year ago.
The company ended the fiscal year with $9.78M in total debt, an increase of 1164.94% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
